ArticleJournal of diabetes research2021
Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema.
Article in Journal of diabetes research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Choroidal Vascular Remodeling After Loading Injections of Faricimab in Diabetic Macular Edema.Translational vision science & technology · 2026Article
- Optical Coherence Tomography Biomarkers as Potential Predictors for Visual Function and Response to Intravitreal Therapy in Diabetic Macular Edema.Journal of vitreoretinal diseases · 2026Article
- Early dynamic response on spectral-domain OCT predicts long-term visual outcome in diabetic macular edema treated with aflibercept.BMC ophthalmology · 2026Article
- Multimodal imaging biomarkers associated with recurrence of diabetic macular edema during aflibercept treat-and-extend therapy.Scientific reports · 2026Article
- Region-Specific Retinal and Choroidal Biomarkers Associated with Visual Outcomes After Anti-VEGF Treatment in Center-Involved Diabetic Macular Edema.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Comparative value of retinal structural features versus systemic inflammatory and renal indicators in predicting short-term anti-VEGF response in diabetic macular edema: focus on OCT biomarkers.Frontiers in medicine · 2026Article
- Diagnostic value of choroidal vascular density in predicting the progression of diabetic retinopathy.Scientific reports · 2025Article
- Prospective and dichotomous study of biomarkers with swept-source OCT and OCT-angiography in naive patients with diabetic macular edema.International journal of retina and vitreous · 2025Article
- Associations of Retinal Vessel Geometry and Optical Coherence Tomography Angiography Metrics With Choroidal Metrics in Diabetic Retinopathy.Investigative ophthalmology & visual science · 2024Article
- Postoperative choroidal vascularity index after the management of macula-off rhegmatogenous retinal detachment.International journal of retina and vitreous · 2023Review
- Quantitative Assessment of Choroidal Thickness and Choroidal Vascular Features in Healthy Eyes Based on Image Binarization of EDI-OCT: A Single-Center Cross-Sectional Analysis in Chinese Population.Journal of clinical medicine · 2023Article
- Prognostic value of choroidal vascular index in determining response to intravitreal dexamethasone implant treatment used in refractory diabetic macular edema.Lasers in medical science · 2023Article
- Short-term Effects of Intravitreal Dexamethasone Implant on Choroidal Structure in Eyes with Refractory Diabetic Macular Edema.Beyoglu eye journal · 2023Article
- Choroidal Structural Changes of Posterior Subtenon Triamcinolone Acetonide Injection in Eyes with Refractory Diabetic Macular Edema.Journal of ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the choroidal vascularity index (CVI) as a prognostic factor for the visual efficacy of antivascular endothelial growth factor (VEGF) treatment in diabetic macular edema (DME).
methodsWe retrospectively reviewed 92 DME eyes receiving anti-VEGF treatment, which were stratified as responders (≥5 letters gained) and nonresponders (<5 letters gained or lost). Baseline systematic features and optical coherence tomography features, including the CVI, adjusted ellipsoid zone (EZ) reflectivity, subretinal fluid (SRF), and disorganization of the retinal inner layers (DRIL), were evaluated between the two groups.
resultsThe baseline CVI was significantly lower in nonresponders than in responders (0.66 ± 0.05, 0.69 ± 0.05, and 0.72 ± 0.05,
conclusionDME patients with a higher CVI, higher adjusted EZ reflectivity, the presence of SRF, and the absence of DRIL at baseline were more likely to gain >5 letters in visual acuity after anti-VEGF treatment. CVI may serve as a novel biomarker for visual response to anti-VEGF treatment in DME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.